When it comes to investing, sometimes thinking small is best, says Forbes' Yuval Bar-Or. Progress in technology and innovative products associated with DNA sequencing and the human genome could mean investment opportunities. As the $1,000 (or cheaper) genome approaches, the implications are "at once wondrous and disturbing," says Bar-Or, who hold investments in Illumina and Life Technologies. "Ongoing discoveries will usher in a new age of gene-based products and services. Savvy investors will undoubtedly reap rich rewards," he adds. Even considering the possible ethical and legal challenges that will ensue as technology becomes more and more advanced, it's doubtful that these problems will slow the growth of companies that manufacture the technology, Bar-Or says.
Investing in DNA
Jun 09, 2011